NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.530
+0.140 (5.86%)
At close: Aug 13, 2025, 4:00 PM
2.730
+0.200 (7.91%)
Pre-market: Aug 14, 2025, 8:59 AM EDT
NRx Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for NRx Pharmaceuticals stock ranges from a low of $18 to a high of $46. The average analyst price target of $28.5 forecasts a 1,026.48% increase in the stock price over the next year.
Price Target: $28.50 (+1,026.48%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +1,125.30% | Aug 11, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +1,125.30% | Aug 4, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +1,125.30% | Jun 23, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +1,125.30% | Jun 20, 2025 |
D. Boral Capital | D. Boral Capital | Strong Buy Maintains $31 | Strong Buy | Maintains | $31 | +1,125.30% | Jun 6, 2025 |
Financial Forecast
Revenue This Year
33.15M
Revenue Next Year
109.71M
from 33.15M
Increased by 230.95%
EPS This Year
-0.13
from -2.36
EPS Next Year
0.71
from -0.13
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | 36.8M | 189.3M | 544.6M | ||
Avg | 33.2M | 109.7M | 296.7M | ||
Low | 29.4M | 41.6M | 61.9M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | 471.0% | 396.4% | ||
Avg | - | 231.0% | 170.5% | ||
Low | - | 25.3% | -43.5% |
EPS Forecast
EPS | 2025 | 2026 | 2027 |
---|---|---|---|
High | 0.16 | 1.62 | 5.18 |
Avg | -0.13 | 0.71 | 2.78 |
Low | -0.39 | 0.05 | 0.51 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 |
---|---|---|---|
High | - | - | 628.5% |
Avg | - | - | 291.1% |
Low | - | - | -28.3% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.